JP2023535073A5 - - Google Patents
Info
- Publication number
- JP2023535073A5 JP2023535073A5 JP2023504634A JP2023504634A JP2023535073A5 JP 2023535073 A5 JP2023535073 A5 JP 2023535073A5 JP 2023504634 A JP2023504634 A JP 2023504634A JP 2023504634 A JP2023504634 A JP 2023504634A JP 2023535073 A5 JP2023535073 A5 JP 2023535073A5
- Authority
- JP
- Japan
- Prior art keywords
- complex according
- exon
- antibody
- oligonucleotide
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026001924A JP7894538B2 (ja) | 2020-07-23 | 2026-01-08 | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063055777P | 2020-07-23 | 2020-07-23 | |
| US63/055,777 | 2020-07-23 | ||
| US202063069077P | 2020-08-23 | 2020-08-23 | |
| US63/069,077 | 2020-08-23 | ||
| US202163143829P | 2021-01-30 | 2021-01-30 | |
| US63/143,829 | 2021-01-30 | ||
| PCT/US2021/040998 WO2022020107A1 (en) | 2020-07-23 | 2021-07-09 | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026001924A Division JP7894538B2 (ja) | 2020-07-23 | 2026-01-08 | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023535073A JP2023535073A (ja) | 2023-08-15 |
| JP2023535073A5 true JP2023535073A5 (enExample) | 2024-07-18 |
| JP7803926B2 JP7803926B2 (ja) | 2026-01-21 |
Family
ID=79728346
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023504634A Active JP7803926B2 (ja) | 2020-07-23 | 2021-07-09 | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
| JP2026001924A Active JP7894538B2 (ja) | 2020-07-23 | 2026-01-08 | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026001924A Active JP7894538B2 (ja) | 2020-07-23 | 2026-01-08 | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230285586A1 (enExample) |
| EP (1) | EP4185330A4 (enExample) |
| JP (2) | JP7803926B2 (enExample) |
| KR (1) | KR20230044242A (enExample) |
| CN (1) | CN116368150A (enExample) |
| AU (1) | AU2021312709A1 (enExample) |
| BR (1) | BR112023001125A2 (enExample) |
| CA (1) | CA3186752A1 (enExample) |
| IL (1) | IL299662A (enExample) |
| MX (1) | MX2023000984A (enExample) |
| WO (1) | WO2022020107A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| EP3830259A4 (en) | 2018-08-02 | 2022-05-04 | Dyne Therapeutics, Inc. | MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| WO2020028832A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| WO2020219820A1 (en) | 2019-04-25 | 2020-10-29 | Avidity Biosciences, Inc. | Nucleic acid compositions and methods of multi-exon skipping |
| WO2021154477A1 (en) | 2020-01-31 | 2021-08-05 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (tfr) antibody and uses thereof |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| AU2021313058A1 (en) * | 2020-07-23 | 2023-03-30 | Dyne Therapeutics, Inc. | Muscle-targeting complexes and uses thereof |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| KR20230117182A (ko) * | 2020-12-04 | 2023-08-07 | 다인 세라퓨틱스, 인크. | 항체-올리고뉴클레오티드 복합체 및 그의 용도 |
| WO2022251181A1 (en) * | 2021-05-25 | 2022-12-01 | The Board Of Regents Of The University Of Texas System | Correction of duchenne muscular dystrophy mutations with all-in-one adeno-associated virus-delivered single-cut crispr |
| JPWO2022270585A1 (enExample) | 2021-06-23 | 2022-12-29 | ||
| CA3226298A1 (en) * | 2021-07-09 | 2023-01-12 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| CN118401553A (zh) * | 2021-07-09 | 2024-07-26 | 达因疗法公司 | 肌肉靶向复合物及其用于治疗肌养蛋白病的用途 |
| CA3226301A1 (en) * | 2021-07-09 | 2023-01-12 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| JP2024525613A (ja) * | 2021-07-09 | 2024-07-12 | ダイン セラピューティクス，インコーポレーテッド | 筋標的化複合体およびジストロフィノパチーを処置するためのその使用 |
| CN118591391A (zh) * | 2021-07-09 | 2024-09-03 | 达因疗法公司 | 肌肉靶向复合物及其用于治疗肌养蛋白病的用途 |
| US20240318176A1 (en) * | 2021-07-09 | 2024-09-26 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| WO2023283623A1 (en) | 2021-07-09 | 2023-01-12 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating dystrophinopathies |
| US12071621B2 (en) | 2022-04-05 | 2024-08-27 | Avidity Biosciences, Inc. | Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| JP2026516311A (ja) | 2023-04-24 | 2026-05-21 | バイオマリン ファーマシューティカル インコーポレイテッド | Ｓｔｘｂｐ１障害を治療するための組成物および方法 |
| KR20260044219A (ko) | 2023-07-21 | 2026-04-01 | 매로우 테라퓨틱스, 인크. | 조혈 세포 표적화 접합체 및 관련 방법 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8734799B2 (en) * | 2010-04-13 | 2014-05-27 | The Regents Of The University Of California | Unconjugated anti-TfR antibodies and compositions thereof for the treatment of cancer |
| AU2011349443B2 (en) * | 2010-12-20 | 2015-12-24 | Genentech, Inc. | Anti-mesothelin antibodies and immunoconjugates |
| RS60593B1 (sr) * | 2014-01-24 | 2020-08-31 | Ngm Biopharmaceuticals Inc | Antitela koja vezuju domen 2 beta-kloto i postupci za njihovu upotrebu |
| CA2990785C (en) * | 2015-06-24 | 2024-11-12 | Jcr Pharmaceuticals Co., Ltd. | ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODIES CROSSING THE BLOOD-BRAIN BARRIER |
| FR3049951A1 (fr) * | 2016-04-12 | 2017-10-13 | Univ Rabelais Francois | Nouvelles constructions peptidiques et leur utilisation dans le traitement de la toxoplasmose |
| SG11202002517RA (en) * | 2017-09-22 | 2020-04-29 | Avidity Biosciences Inc | Nucleic acid-polypeptide compositions and methods of inducing exon skipping |
| UY38247A (es) * | 2018-05-30 | 2019-12-31 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
| AU2019315593B2 (en) | 2018-08-02 | 2026-05-21 | Dyne Therapeutics, Inc. | Muscle-targeting complexes and uses thereof |
| EP3829594A4 (en) * | 2018-08-02 | 2022-05-11 | Dyne Therapeutics, Inc. | MUSCLE TARGETING COMPLEXES AND THEIR USES FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY |
| WO2020028832A1 (en) * | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| JP7700039B2 (ja) * | 2019-01-04 | 2025-06-30 | マレンゴ・セラピューティクス，インコーポレーテッド | 抗ｔｃｒ抗体分子およびその使用 |
| US20230111212A1 (en) * | 2020-01-10 | 2023-04-13 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| AU2021313058A1 (en) * | 2020-07-23 | 2023-03-30 | Dyne Therapeutics, Inc. | Muscle-targeting complexes and uses thereof |
| US20230256112A1 (en) * | 2020-07-23 | 2023-08-17 | Dyne Therapeutics, lnc. | Anti-transferrin receptor (tfr) antibody and uses thereof |
-
2021
- 2021-07-09 MX MX2023000984A patent/MX2023000984A/es unknown
- 2021-07-09 KR KR1020237005853A patent/KR20230044242A/ko active Pending
- 2021-07-09 AU AU2021312709A patent/AU2021312709A1/en active Pending
- 2021-07-09 CA CA3186752A patent/CA3186752A1/en active Pending
- 2021-07-09 JP JP2023504634A patent/JP7803926B2/ja active Active
- 2021-07-09 WO PCT/US2021/040998 patent/WO2022020107A1/en not_active Ceased
- 2021-07-09 EP EP21846687.8A patent/EP4185330A4/en active Pending
- 2021-07-09 BR BR112023001125A patent/BR112023001125A2/pt unknown
- 2021-07-09 CN CN202180064570.5A patent/CN116368150A/zh active Pending
- 2021-07-09 IL IL299662A patent/IL299662A/en unknown
- 2021-07-09 US US18/017,179 patent/US20230285586A1/en active Pending
-
2026
- 2026-01-08 JP JP2026001924A patent/JP7894538B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023510350A5 (enExample) | ||
| JP2024527362A5 (enExample) | ||
| JP2021533197A5 (enExample) | ||
| JP2021532831A5 (enExample) | ||
| JP2024525610A5 (enExample) | ||
| JP2023512441A5 (enExample) | ||
| JP2021533199A5 (enExample) | ||
| JP2021533198A5 (enExample) | ||
| JP2024525611A5 (enExample) | ||
| JP2023535078A5 (enExample) | ||
| JP2023509793A5 (enExample) | ||
| JP2021532832A5 (enExample) | ||
| JP2021533200A5 (enExample) | ||
| JP2024525613A5 (enExample) | ||
| JP2023512442A5 (enExample) | ||
| JP2024160045A5 (enExample) | ||
| JP2024525612A5 (enExample) | ||
| IL309937A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309909A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| JP2023015095A5 (enExample) | ||
| JP2025067909A5 (enExample) | ||
| JP2024524222A5 (enExample) | ||
| JP2023510351A5 (enExample) | ||
| IL309935A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309911A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies |